Statins, leptin and regulatory T cells

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 18, Issue 6, 2008, Pages

  Goldstein, Mark R ^a   Mascitelli, Luca ^b   Pezzetta, Francesca ^c  

^a Fountain Medical Court ^*  (United States)

^b Servizio Sanitario ^*  (Italy)

^c Ospedale Civile di Tolmezzo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; LEPTIN; PYRROLE DERIVATIVE;

ANIMAL; BODY WEIGHT; DRUG EFFECT; HUMAN; IMMUNOLOGY; LETTER; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; OBESITY; REGULATORY T LYMPHOCYTE; RISK FACTOR;

ANIMALS; HEPTANOIC ACIDS; HUMANS; LEPTIN; LYMPHOCYTE ACTIVATION; NEOPLASMS; OBESITY; PYRROLES; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; THINNESS;

EID: 46249100131     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.01.001     Document Type: Letter

References (9)

1. Taleb S., Herbin O., Ait-Oufella H., Verreth W., Gourdy P., Barateau V., et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2691-2698
2. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
3. Goldstein M.R. Cholesterol lowering in patients with CHD and metabolic syndrome. Lancet 369 (2007) 25
4. Alsheikh-Ali A.A., Maddukuri P.V., Han H., and Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50 (2007) 409-418
5. Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+ CD25+ T cells. Atherosclerosis [Epub 2007 Sept 10].
6. Mallat Z., Ait-Oufella, and Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 16 (2005) 518-524
7. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
8. The PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
9. O'Keefe Jr. J.H., Cordain L., Harris W.H., Moe R.M., and Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 43 (2004) 2142-2146